Alfuzosin Other names: Alfuzosin hydrochloride

Chemical formula: C₁₉H₂₇N₅O₄  Molecular mass: 389.449 g/mol  PubChem compound: 2092

Active ingredient description

Alfuzosin is an orally active quinazoline derivative. It is a selective, peripherally acting antagonist of postsynaptic alpha-1-adrenoceptors. In vitro pharmacological studies have documented the selectivity of alfuzosin for the alpha-1-adrenoreceptors located in the prostate, bladder base and prostatic urethra.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
G04CA01 Alfuzosin G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists
Discover more medicines within G04CA01

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
XATRAL XL Prolonged release tablets Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 81403-68-1
CAS Substance: 81403-80-7
DrugBank Drug: DB00346
KEGG Drug: D07124
PubChem Compound: 2092
RxNorm Ingredient: 17300
SNOMED-CT Concept: 395954002
Alfuzosin (substance)
UNII Identifier: 90347YTW5F
ALFUZOSIN

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.